CORRECTION



Correction to: Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT

Dédée F. Murrell · Pascal Joly · Victoria P. Werth · Hideyuki Ujiie ·

Margitta Worm \cdot Aaron R. Mangold \cdot Elena Avetisova \cdot

Jennifer Maloney \cdot Elizabeth Laws \cdot Eric Mortensen \cdot Ariane Dubost-Brama \cdot Arsalan Shabbir

Published online: May 24, 2024 © Crown 2024

Correction to: Adv Ther https://doi.org/10.1007/s12325-024-02810-3

In the sentence beginning 'A Cochrane Review...' in this article, the term TCSs should have read 'TCS'.

The original article can be found online at https://doi. org/10.1007/s12325-024-02810-3.

D. F. Murrell (⊠) Department of Dermatology, St George Hospital, University of New South Wales, Sydney, NSW, Australia e-mail: d.murrell@unsw.edu.au

P. Joly Rouen University Hospital and INSERM 1234, Normandy University, Rouen, France e-mail: Pascal.Joly@chu-rouen.fr

V. P. Werth Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

V. P. Werth Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA e-mail: Victoria.Werth@pennmedicine.upenn.edu

H. Ujiie Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan e-mail: h-ujiie@med.hokudai.ac.jp In the sentence beginning 'In clinical...' in this article, the value '312' should have read '2312'.

In the sentence beginning 'Werth is a...' in this article, the text 'Lily' should have read 'Eli Lily'.

The original article has been corrected.

Open Access. This article is licensed under a Creative Commons Attribution-Non-Commercial 4.0 International License, which permits any non-commercial use, sharing,

M. Worm

Charité-Universitätsmedizin Berlin, Berlin, Germany e-mail: margitta.worm@charite.de

A. R. Mangold Department of Dermatology, Mayo Clinic, Scottsdale, AZ, USA e-mail: mangold.aaron@mayo.edu

E. Avetisova \cdot J. Maloney \cdot E. Mortensen \cdot A. Shabbir Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA

E. Avetisova e-mail: yelena.avetisova@regeneron.com

J. Maloney e-mail: jennifer.maloney@regeneron.com

E. Mortensen e-mail: eric.mortensen@regeneron.com

A. Shabbir e-mail: arsalan.shabbir@regeneron.com adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creativecommons.org/licenses/by-nc/4.0/.

E. Laws Sanofi, Bridgewater, NJ, USA e-mail: elizabeth.laws@sanofi.com

A. Dubost-Brama Sanofi, Chilly-Mazarin, France e-mail: Ariane.DUBOST-BRAMA@sanofi.com

D. F. Murrell The Church, 17 Kensington St, Kogarah, NSW 2217, Australia